Financials

  • Market Capitalization 1.82 B
  • Employee 110
  • Founded 2024
  • CEO N/A
  • Website www.inhibrx.com
  • Headquarter Delaware, United States
  • FIGI BBG01MS5Q9G3
  • Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-8.74
Rapporto prezzo/fatturato
941.13

Related tickers

#NomePrezzo24h %7d %1M %1Y %Valore di MercatoUltimi 7 Giorni
2048
TSHA
Taysha Gene Therapies, Inc. - Common Stock
5.77 USD-3.19%-4.15%+2.85%+98.97%1.88 B USD
2064
VIR
Vir Biotechnology, Inc. - Common Stock
10.83 USD-4.24%+11.19%+25.78%+81.10%1.83 B USD
2071
SEPN
Septerna, Inc. - Common Stock
38.91 USD-3.85%-3.31%+14.44%+76.78%1.82 B USD
2076
NTLA
Intellia Therapeutics, Inc. - Common Stock
12.87 USD-1.83%+2.14%+17.97%-6.20%1.80 B USD

Notizie